The Efficacy and Safety of PD-1/PD-L1 Inhibitors Combined With Centipeda Minima (CM) in Lung Cancer
Status:
Not yet recruiting
Trial end date:
2025-02-07
Target enrollment:
Participant gender:
Summary
Lung cancer has a high global cancer morbidity and mortality. At present, PD-1/PD-L1
inhibitors have been approved by FDA to treat different types of lung cancer, but the
efficacy is not good. There is an urgent need to develop drugs that can significantly enhance
the efficacy of PD-1/PD-L1 inhibitors to enable tumor patients to obtain lasting anti-tumor
response. Centipeda minima (CM), as a commonly used traditional Chinese medicine, is
relatively safe. Previous studies found that it can inhibit the growth of lung cancer cells.
At the level of animal research, the combined use of CM and PD-1/PD-L1 inhibitors produced a
stronger anti-lung cancer effect, and did not produce obvious side effects on mice. Based on
previous studies, the main purpose of this study was to evaluate the efficacy and safety of
PD-1/PD-L inhibitors combined with herbivorous herbivores (CM) in the treatment of lung
cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University